Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

MOTS-c peptide icon, one bubble per amino acidMOTS-c16 residuesMRWQEMGYIFYPRKLREach bubble = one amino acid. Size = residue mass. Color = chemical class.

MOTS-c

Beginner tier: 5 mg, 3x/week · community consensus

MetabolicPreclinical
~1-2 hours half-life·Injection

Also known as: MOTS-c, MOTSc

Get an alert when FDA rules on MOTS-c

Follow every legal or FDA change, MOTS-c included. By default, alerts come as one weekly push that names the peptides.

Skeletal muscle MOTS-c levels spike up to 12-fold after a single bout of exercise, then decline steadily with age. The MOTS-c peptide is a 16-amino-acid sequence encoded directly in mitochondrial DNA, one of fewer than ten known signaling molecules produced by the mitochondrial genome. Lee and colleagues showed it reduces obesity and corrects insulin resistance in mice [1]. No completed human therapeutic trial exists yet. Preclinical data is strong, community adoption is growing, and the mechanism, AMPK activation via folate cycle inhibition, overlaps directly with the pathways triggered by physical training.

What Is MOTS-c?

Skeletal muscle produces 12 times more MOTS-c during exercise than at rest. That single finding about the MOTS-c peptide, confirmed by Reynolds and colleagues in 2021 [2], reframed this molecule from a curiosity to one of the most studied mitochondrial-derived peptides in metabolic research.

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino-acid peptide encoded in the 12S rRNA gene of mitochondrial DNA. Its molecular weight is 2174.5 Da, and it belongs to a small family of mitochondrial-derived peptides that also includes humanin. The mechanism centers on folate cycle inhibition in skeletal muscle. Blocking de novo purine biosynthesis triggers AMP-activated protein kinase (AMPK), the same energy-sensing enzyme switched on during physical exercise. Once active, AMPK drives GLUT4 translocation, increases fatty acid oxidation, and shifts cellular metabolism away from storage and toward energy production.

The 2015 mouse study by Lee and colleagues [1] remains foundational: MOTS-c reduced diet-induced obesity and restored insulin sensitivity. A 2025 study in Experimental & Molecular Medicine [3] extended the picture by showing MOTS-c prevents pancreatic beta-cell senescence; circulating levels were reduced in patients with type 2 diabetes. Yin and colleagues reported anti-cancer activity in ovarian cancer models (Advanced Science, 2024).

Community users run it at 5 to 10 mg subcutaneous, 2 to 3 times per week, cycling 4 weeks on and 2 to 4 weeks off. Those doses are far below the animal study range of 0.5 to 15 mg/kg/day. Effects are consistent but subtle: improved fasting energy, better exercise tolerance, and modest body composition changes over a cycle. MOTS-c is preclinical and WADA-prohibited. FDA's Category 2 page (current as of April 22, 2026) lists it as withdrawn by its nominators, and PCAC discussed it on July 23, 2026.

How MOTS-c Works

MOTS-c works through a chain of metabolic events that starts with folate. The peptide inhibits the folate cycle and its connected de novo purine biosynthesis pathway in skeletal muscle. That metabolic disruption generates ZMP-like intermediates that activate AMPK.

Once AMPK is engaged, three downstream effects follow. First, GLUT4 translocates to the cell membrane, pulling glucose into the cell independently of insulin. Second, fatty acid oxidation ramps up. Third, the cell shifts its energy balance from storage toward production. These are the same metabolic shifts triggered by aerobic exercise.

Under metabolic stress (glucose restriction or oxidative challenge), MOTS-c does something unexpected. It moves from the cytoplasm into the nucleus through an AMPK-dependent mechanism. Inside the nucleus, it binds to antioxidant response element (ARE) regions of DNA and works with the transcription factor NRF2 to activate stress-response genes. Kim and colleagues mapped this pathway in 2018 [4]. This mitochondria-to-nucleus retrograde signaling allows mitochondria to directly influence nuclear gene expression when the cell is under strain.

Endogenous production matters. Reynolds et al. [2] confirmed that MOTS-c levels in skeletal muscle increase up to 12-fold after acute exercise in humans. Those levels decline with aging, tracking closely with age-related metabolic dysfunction.

MOTS-c Benefits

  • MOTS-c benefits center on metabolic optimization and exercise-like pathway activation.
  • Reduced obesity and improved insulin resistance in diet-induced obese mice, with measurable restoration of glucose homeostasis (Lee et al. 2015)[1].
  • AMPK activation mimics exercise physiology, triggering GLUT4 translocation and fatty acid oxidation without physical training (preclinical models).
  • Community users report improved fasted morning energy and reduced post-exercise fatigue within 1 to 2 weeks of starting a 5 mg, 3x/week protocol.
  • Pancreatic beta-cell protection confirmed in a 2025 Experimental & Molecular Medicine study [3]; circulating MOTS-c levels were measurably lower in type 2 diabetes patients.
  • Body composition shifts over 4 to 6 week cycles: modest fat reduction with lean mass preservation, most pronounced in metabolically compromised users.
  • Anti-cancer activity in ovarian cancer cells and mice: MOTS-c slowed tumor growth by driving breakdown of the cancer-promoting protein LARS1 (Yin et al. 2024, Advanced Science, PMID 39321430 (opens in a new tab)).

MOTS-c: Science vs Community Consensus

Partially Aligned
Scientific Evidence
Moderate
Based on 13 key studies·Preclinical

Well-established AMPK activator in preclinical models with confirmed exercise-mimetic, insulin-sensitizing, and anti-aging effects.

Dosing studied: No human therapeutic dose established. Animal studies: 0.5–15 mg/kg/day SC/IP. Community extrapolates to 5–10 mg absolute dose 2-3x/week (far below weight-adjusted animal doses).
Read the evidence (key study, limitations)

Human data is observational only: endogenous MOTS-c levels correlate with metabolic health markers across multiple human studies. No completed therapeutic trials with native MOTS-c. Analog CB4211 completed Phase 1b. Anti-senescence data strong in 2025 Experimental & Molecular Medicine study (pancreatic beta cells). Anti-cancer activity emerging (2024 Advanced Science ovarian cancer study).

Key Study

Lee et al. 2015 (PMID 25738459): seminal study: MOTS-c reduces obesity and improves insulin resistance in mice. Reynolds et al. 2021 (PMID 33473109): MOTS-c is exercise-induced and declines with aging in humans. Kong et al. 2025 (PMID 40855115): MOTS-c prevents pancreatic beta-cell senescence; circulating levels are reduced in T2D patients.

Limitations

No completed human therapeutic trials with native MOTS-c. All efficacy data from rodent models. No formal SC pharmacokinetics in humans: plasma half-life (~1-2 hours) is inferred from endogenous exercise kinetics, not a dedicated PK study. Conflicting oncology data: some AMPK mechanisms are oncosuppressive while others may promote cancer cell survival depending on tumor type and context. WADA-prohibited: no regulatory oversight of community sourcing.

Community Experience
Moderate
3.8/5
Based on moderate: estimated 500-2,000 active community users. ~50-150 top threads on r/Peptides. Disproportionately represented in longevity/biohacker communities vs. mainstream peptide users.

Positively regarded in metabolic health and longevity biohacker communities.

Community dosing: 5–10 mg per injection, 2-3x/week. Some use low daily titration (200 mcg–1 mg/day). Cycling: 4 weeks on / 2-4 weeks off (most common) or 8 weeks on / 8 weeks off (Jay Campbell).
Read the reports (what users report 5, common issues 5)

Viewed as a "background" metabolic optimizer: effects are consistent but subtle compared to more dramatic single-compound peptides. Most users run in multi-peptide mitochondrial stacks. High per-cycle cost limits community sample size.

What users report (5)
  • Improved fasted morning energy and reduced post-exercise fatigue (within 1-2 weeks)
  • Modest fat loss and body composition improvement over 4-6 week cycles
  • Better glucose regulation and reduced insulin resistance in metabolically compromised users
  • Increased endurance and exercise capacity: notably in aerobic output
  • Longevity and mitochondrial support effects reported when stacked with SS-31 and Epitalon
Common issues (5)
  • High cost per cycle ($150-400+) with variable subjective response; some users report no perceptible effect
  • Injection site irritation: redness, swelling, bruising at injection site
  • Insomnia and sleep disruption when dosed in the afternoon or evening (AMPK-mediated energy signal)
  • WADA-prohibited: athletes using MOTS-c risk competition eligibility
  • Listed as withdrawn from FDA Category 2 as of April 22, 2026; no 503A bulks rule has issued, so compounding pharmacies cannot use it today (PCAC discussed it July 23, 2026); research-grade products only
Partially Aligned

Science and community agree on core mechanism (AMPK activation, exercise mimetic, metabolic improvement) and general outcomes. The dose gap is meaningful: animal studies use 0.5–15 mg/kg while community uses flat 5-10 mg regardless of body weight: for a 70 kg person, that is 0.07-0.14 mg/kg, far below animal study doses. Community effects at these doses are biologically plausible given AMPK sensitivity to small-molecule activators but remain unvalidated in formal human trials.

MOTS-c Dosage Guide

CommunityCommunity dosing consensus from peptide research communities
LevelDose / InjectionFrequency
Beginner5 mg
3x/weekTrack
Moderate10 mg
3x/weekTrack
Aggressive10 mg
5x/weekTrack
Note:

Reconstitution math for a 10 mg vial: add 2 mL bacteriostatic water to get 5 mg/mL. A full 100-unit (1.0 mL) insulin syringe then delivers exactly 5 mg. For the 10 mg dose, you'll draw 200 units (2.0 mL), which means splitting between two injection sites at 100 units each. One 10 mg vial equals one dose at the intermediate level.

For 5 mg vials: add 1 mL BAC water for the same 5 mg/mL concentration. A full syringe equals the full vial.

The thing most beginners miss is timing. MOTS-c fires up AMPK, and that energy signal will keep you awake if you inject past early afternoon. Dose upon waking or 30 to 60 minutes before training. Never after 2 PM.

Store lyophilized powder at -20 degrees Celsius. Once reconstituted, refrigerate at 2 to 8 degrees Celsius and use within 28 days. Confirm vial labels are in mg, not mcg; the community doses MOTS-c in milligrams and a mg/mcg mix-up creates a 1,000-fold error.

Calculate your MOTS-c dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

MOTS-c Protocols by Goal

beginnerCommunity4 weeks on, 2-4 weeks off
Active cycle
Wk 1-4
5 mg · 3x/week · Subcutaneous

Expected: Mild energy improvement within 1-2 weeks. Modest fasting glucose reduction and improved exercise tolerance by week 4. Body composition changes minimal at 5 mg dose.

Monitor: Check fasting glucose at baseline and week 4. If on glucose-lowering medications, monitor more frequently: additive insulin-sensitizing effects can lower glucose meaningfully.

How to Inject MOTS-c

  1. 1
    Step 1

    Pull 2 mL of bacteriostatic water into a syringe and inject slowly into a 10 mg MOTS-c vial, aiming at the glass wall. Let the powder dissolve without shaking. This gives you a 5 mg/mL concentration.

  2. 2
    Step 2

    For a 5 mg dose, draw 100 units (1.0 mL) on a standard U-100 insulin syringe. For a 10 mg dose, draw the full 200 units (2.0 mL) and split between two injection sites.

  3. 3
    Use a 29 to 31 gauge insulin syringe

    Pinch a fold of skin at your injection site (abdomen, thigh, or upper arm) and insert at a 45-degree angle.

  4. 4
    Inject slowly, no faster than 10 seconds per mL

    At the 10 mg dose, inject 100 units at the first site, then move to a second site (e.g., opposite side of the abdomen) for the remaining 100 units.

  5. 5
    Rotate injection sites with each dose

    If you inject three times per week, use at least three distinct sites in rotation to avoid local irritation buildup.

  6. 6
    Dose upon waking or 30 to 60 minutes before training

    Do not inject after 2 PM.

  7. 7
    Step 7

    After reconstitution, store the vial in the refrigerator at 2 to 8 degrees Celsius. Discard after 28 days. Keep unreconstituted vials frozen at -20 degrees Celsius.

Mixing your own vial? Use the MOTS-c reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

MOTS-c Stacking Protocols

Works With

Avoid

Metformin

Both MOTS-c and metformin activate AMPK via overlapping mechanisms. Additive AMPK stimulation significantly increases risk of excessive glucose lowering. Community consensus: avoid unless under physician supervision with active glucose monitoring.

Do not combine
Insulin / Sulfonylureas

MOTS-c promotes insulin-independent GLUT4-mediated glucose uptake. Combined with exogenous insulin or insulin secretagogues, hypoglycemia risk is clinically significant, particularly in fasted or pre-training states.

Do not combine
Antifolates (Methotrexate, Trimethoprim)

MOTS-c's primary mechanism involves inhibiting the folate cycle. Concurrent antifolate drugs may produce unpredictable additive or antagonistic effects on folate metabolism.

Berberine

Berberine is a potent AMPK activator. Combining with MOTS-c creates overlapping AMPK stimulation with unpredictable magnitude of glucose-lowering effect.

How much does MOTS-c cost?

Typical price

$3.90 to $6.36 per mg

Typical $4.65

Middle half of 124 US prices for 10 mg vials · read Oct 31

See prices

Free account. Not a pharmacy price: these are vials sold online, and none is an FDA-approved medicine.

Compounded
Not available from compounding pharmacies today. MOTS-c is listed as withdrawn from FDA Category 2 as of April 22, 2026. PCAC discussed it on July 23, 2026; no FDA rule has added it to the 503A bulks list.

Pricing updated 2026-04-09

MOTS-c Side Effects

The most serious risk with MOTS-c is hypoglycemia, particularly for anyone taking metformin, insulin, sulfonylureas, or berberine alongside it. MOTS-c activates AMPK and promotes insulin-independent glucose uptake through GLUT4 translocation. Stack that mechanism on top of another AMPK activator or glucose-lowering drug, and fasting glucose can drop fast. Users on these medications should monitor blood glucose actively and discuss timing adjustments with their prescribing physician.

No completed human therapeutic trial exists for native MOTS-c. All efficacy and safety data come from animal models and observational human studies. The CB4211 analog completed Phase 1b, but that is a modified compound with its own safety profile. Community experience provides the largest real-world dataset: an estimated 500 to 2,000 active users, with roughly 50 to 150 identifiable threads on r/Peptides. That sample size is modest, and rare adverse events may not yet have surfaced.

Injection site reactions are the most commonly reported side effect. Redness, mild swelling, and occasional bruising at the injection site appear frequently in first-week reports. At the 10 mg dose (2 mL injection volume), splitting between two sites at 1 mL each reduces local irritation. Warming the vial to room temperature before injecting also helps.

Insomnia and sleep disruption rank second. MOTS-c activates cellular energy metabolism through AMPK, and dosing after 2 PM produces an energy signal that interferes with sleep onset. Community consensus is strict: morning dosing only, upon waking. Sleep issues resolve within 1 to 2 days of switching to morning-only administration for most users.

MOTS-c inhibits the folate cycle as its primary mechanism. Anyone taking antifolate medications (methotrexate, trimethoprim) should exercise caution. The interaction is theoretically bidirectional: MOTS-c could increase antifolate toxicity or reduce efficacy depending on context. No clinical data clarifies this interaction.

Conflicting oncology data exists. Some AMPK-mediated mechanisms are oncosuppressive; others may promote cancer cell survival depending on tumor type. The 2024 Advanced Science study showed anti-cancer activity in ovarian cancer, but this cannot be generalized across all cancers.

Pregnancy and breastfeeding are absolute contraindications. Children and adolescents lack sufficient safety data. Individuals with severe hepatic impairment should use MOTS-c only under clinical supervision, as the peptide is under active research for non-alcoholic fatty liver disease.

Stop MOTS-c and consult a physician if fasting glucose drops below 70 mg/dL, if sleep disruption persists despite morning-only dosing, or if injection site reactions do not resolve with site rotation and technique correction.

Common Issues & Solutions

Insomnia or elevated energy at night? MOTS-c activates AMPK, which increases cellular energy metabolism. Dosing after 2 PM produces an energy signal that conflicts with sleep onset. Strict morning dosing (upon waking) resolves this for most users within 1-2 days of adjustment.

Not measuring any effects after 2 weeks? Check reconstitution math first: 10 mg vial in 2 mL BAC water = 5 mg/mL. A full 100-unit (1.0 mL) insulin syringe = 5 mg. Confirm you are injecting the correct volume. At 5 mg 3x/week, effects are subtle: this compound is a metabolic optimizer, not a dramatic stimulant.

Injection site redness or lumps? Rotate sites (abdomen, thigh, upper arm). At the 10 mg dose (2 mL volume), always split between two sites at 1 mL each. Inject slowly: no faster than 10 seconds per mL. Warming the vial to room temperature before injection reduces site irritation.

Low energy or dizziness during the cycle while taking metformin or berberine? Both compounds activate AMPK. The combined glucose-lowering effect can cause hypoglycemia: especially fasted. Check blood glucose immediately. Discuss with your prescribing physician about timing or dose adjustments.

Cost is unsustainable at 10 mg 3x/week? One 10 mg vial per injection at $40-100 per vial = up to $300/week. Most community members step down to 5 mg 3x/week for maintenance cycles or switch to 5 mg daily dosing to stretch vials further.

Ask AI about this page

Ask AI for a second opinion on MOTS-c dosing and side effects

Contraindications

  • Pregnancy or breastfeeding
  • Active hypoglycemia or insulin-dependent diabetes without physician oversight
  • Known hypersensitivity to mitochondrial-derived peptides
  • Children and adolescents (insufficient safety data)
  • Severe hepatic impairment (MOTS-c is being studied in hepatic steatosis: use only under clinical supervision)
  • Active cancer (conflicting AMPK oncology data; some AMPK mechanisms may promote cancer cell survival depending on tumor type)

Drug Interactions

  • Metformin and other AMPK activators: potential additive effect on glucose lowering and AMPK signaling; monitor for hypoglycemia
  • Insulin and sulfonylureas: combined insulin-sensitizing effects may increase hypoglycemia risk
  • Folate supplements and antifolates (methotrexate): MOTS-c inhibits the folate cycle, which could alter drug efficacy or toxicity
  • Thiazolidinediones (pioglitazone, rosiglitazone): overlapping insulin-sensitizing pathways may produce additive effects

Product Quality

Recommended Monitoring

TestWhenTarget
Fasting blood glucoseBaseline, mid-cycle (week 2), and end of cycle70-100 mg/dL fasted. Stop or reduce dose if consistently below 70 mg/dL or if symptomatic hypoglycemia occurs.
HbA1cBaseline and 3 months post-cycle<5.7% (normal); <7.0% (T2D management target).
Liver function panel (ALT, AST)Baseline and end of cycle (for cycles >6 weeks)ALT <40 U/L, AST <40 U/L. Any >2× elevation above baseline warrants stopping.
Lipid panel (total cholesterol, LDL, HDL, triglycerides)Baseline and post-cycleNot listed
Fasting blood glucose

MOTS-c promotes GLUT4-mediated insulin-independent glucose uptake. Combined with glucose-lowering medications, fasting glucose can drop significantly.

HbA1c

Primary marker for sustained insulin sensitivity improvement. Most relevant for users with pre-diabetes or T2D. Improvement of ≥0.3 percentage points reflects meaningful metabolic effect.

Liver function panel (ALT, AST)

MOTS-c is under active research for non-alcoholic fatty liver disease (NAFLD). Hepatic effects are biologically plausible. Monitoring is prudent for extended cycles or users with known hepatic conditions.

Lipid panel (total cholesterol, LDL, HDL, triglycerides)

MOTS-c increases fatty acid oxidation. Beneficial shifts in triglycerides and HDL are plausible metabolic markers. Useful for objectively quantifying metabolic response over a cycle.

MOTS-c Before and After

Week 1

Minimal noticeable effects. Some users report mildly increased energy levels. AMPK activation begins at the cellular level but outward changes are not yet apparent.

Weeks 2-3

Improved exercise tolerance and endurance may become noticeable. Fasting glucose levels may begin trending downward. Mild increase in daily energy expenditure.

Weeks 4-6

Measurable improvements in insulin sensitivity and fasting glucose. Enhanced fatty acid oxidation may contribute to modest changes in body composition. Exercise recovery time may decrease.

Weeks 6-8

Peak metabolic benefits typically observed. Improved glucose regulation, better exercise capacity, and sustained energy levels throughout the day. Body composition improvements become more apparent.

Post-cycle
off period

Benefits gradually diminish over 2-4 weeks after discontinuation. Endogenous MOTS-c production continues but at baseline levels. Most users follow a 4-weeks-on, 2-weeks-off cycle pattern.

What to Expect

Week 1, AMPK activation begins: AMPK fires within hours of each dose through folate cycle inhibition. GLUT4 translocation increases glucose uptake at the cellular level. Some users notice a mild uptick in energy. Most report no dramatic single-compound effect this early. Injection site redness is common in the first few sessions. Do not dose after 2 PM; insomnia reports spike when users ignore this timing rule.

Weeks 2 to 3, metabolic shift becomes noticeable: Sustained AMPK activation drives measurable changes in fat oxidation and glucose handling. MOTS-c begins translocating into the nucleus under metabolic stress, activating NRF2 target genes. Community users report improved exercise tolerance, shorter post-exercise fatigue, and more consistent daily energy. Fasting glucose trends lower in metabolically compromised users. Sensitive individuals may still experience mild sleep disruption despite morning dosing.

Weeks 4 to 6, peak metabolic benefits: This is the window most users rate highest (3.8 out of 5 overall sentiment). Body composition improvements become visible. Glucose regulation clearly improves. Exercise capacity hits its best point during the cycle and recovery time shortens. Cumulative GLUT4 and fatty acid oxidation effects reach their maximum. Injection site fatigue from repeated rotation is the main complaint at this stage.

Post-cycle (off period), washout and normalization: MOTS-c clears rapidly after each dose (plasma half-life approximately 1 to 2 hours). AMPK activity returns to endogenous baseline. Benefits taper over 2 to 4 weeks. Users who maintained training throughout the cycle retain effects longer. Metabolic improvements in glucose handling and body composition appear partially maintained across multiple cycles. Most users follow a 4 weeks on, 2 to 4 weeks off pattern before beginning another cycle.

Detailed Timeline: Science vs Community

Week 1
Science

AMPK is activated within hours of each dose via folate cycle inhibition and ZMP-like signaling. GLUT4 translocation increases glucose uptake. Metabolic gene expression begins shifting within 24-48 hours.

Community

Mild increase in energy noted by some. Slight improvement in fasted morning feeling. Most users report no dramatic single-compound effect. Injection site redness common in first week.

Weeks 2-3
Science

Sustained AMPK activation drives measurable shifts in fat oxidation and glucose utilization. MOTS-c begins nuclear translocation under metabolic stress, activating NRF2-mediated stress-response genes. Mitochondrial biogenesis upregulated.

Community

Improved exercise tolerance and endurance. Fasting glucose trending lower in metabolically compromised users. More consistent daily energy. Post-exercise fatigue noticeably shorter.

Weeks 4-6
Science

Maximum cumulative effect on GLUT4-mediated glucose uptake, fatty acid oxidation, and mitochondrial biogenesis gene expression. Insulin sensitivity improvements are measurable in metabolic studies at this timeframe.

Community

Most users report peak benefits: body composition improvements visible, glucose regulation clearly improved, exercise capacity at its best during cycle. Recovery time shorter. This is the window users rate most positively (3.8/5 overall sentiment).

Post-cycle (off period)
Science

MOTS-c plasma half-life is approximately 1-2 hours: compound clears rapidly after each dose. AMPK activity returns to endogenous baseline. Downstream transcriptional adaptations (mitochondrial biogenesis, NRF2 target genes) may persist several weeks but normalize gradually.

Community

Benefits taper over 2-4 weeks post-cycle. More sustained in users who maintained training throughout. Most users return to baseline energy by end of off period. Metabolic improvements (glucose, body composition) appear partially maintained across multiple cycles.

Pharmacokinetics

Half-Life
1.5h
Bioavailability
SC: not formally determined in humans
Tmax
Estimated 1-3 hours (SC)
Data Confidence
low

Source: Exogenous plasma t½ ~1-2 hours inferred from exercise kinetics; endogenous circulating levels persist 12-15 hours (preclinical estimates)

Pharmacokinetics: Active Dose Over Time

t½ = ~1-2 hours (exogenous plasma); ~12-15 hours (endogenous circulating)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
16
Molecular Weight
2,174.63 Da
Sequence
MRWQEMGYIFYPRKLR
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers
CAS: 1627580-64-6

Who Should Consider MOTS-c

  • Adults with insulin resistance or prediabetes
  • Aging individuals experiencing metabolic decline
  • Those seeking exercise-like metabolic benefits during periods of inactivity
  • Individuals with obesity or metabolic syndrome
  • Researchers studying mitochondrial signaling and aging

Related Peptides

What Changed for MOTS-c

  1. Regulatory

    PCAC backed MOTS-c for the 503A bulks list 7-5-2 on Jul 23, 2026, per a law-firm summary; reported from the meeting; FDA has not posted minutes.

    What this does not mean: The vote did not add it to the 503A bulks list. FDA must complete notice-and-comment rulemaking first, and no proposed or final rule exists (Federal Register search, Oct 6, 2026).

    Source: FDA meeting page, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (content current as of 08/06/2026) (opens in a new tab) · Reported by Law-firm client alert, "Bulk-list bound? PCAC backs majority of peptides in two-day public meeting" (Jul 27, 2026) (opens in a new tab) · Saved copy

  2. RegulatoryEffective

    Nominators withdrew 12 peptides (GHK-Cu for injectable routes only) from 503A category 2, announced Apr 15, 2026, per the FDA 503A categories list.

    What this does not mean: Leaving category 2 does not put a peptide on the 503A bulks list or make it eligible for compounding. That takes FDA rulemaking, and none has been proposed (Federal Register search, Oct 6, 2026).

    Also covers: BPC-157, KPV, TB-500, DSIP, Semax, Epithalon, GHK-Cu, LL-37, Dihexa, PEG-MGF, Melanotan II

    Source: FDA, Bulk drug substances nominated for use in compounding under section 503A (categories list, updated April 22, 2026; the April 15, 2026 notice version is archived beside it) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

Peptide Schedule Research TeamReviewed Apr 7, 202612 Citations

References

  1. [1]The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (Lee et al. 2015) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis (Nat Commun 2021) (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes (Exp Mol Med 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress (Kim et al. 2018) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Resources

Related Tools

Storage & Stability

Before Reconstitution
Store at -20°C for long-term stability (up to 2 years). At 2-8°C, stable up to 6 months sealed.
After Reconstitution
Refrigerate at 2-8°C, use within 3-4 weeks
Temperature
-20°C long-term; 2-8°C reconstituted

Frequently Asked Questions

Beginner: 5 mg subcutaneous, 3 times per week. Moderate: 10 mg, 3 times per week. Standard cycle is 4 weeks on, 4 weeks off. Inject in the morning, ideally before exercise. Community protocols favor the 5 mg 3x/week starting dose based on early published data and user reports.

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. It activates AMPK, the same metabolic sensor triggered by exercise and metformin. This improves glucose uptake, increases fatty acid oxidation, and promotes mitochondrial biogenesis. Skeletal muscle produces 12 times more MOTS-c during exercise than at rest (Reynolds 2021, PMID 33473109).

Injection site reactions and mild fatigue are the most commonly reported effects. Some users experience temporary GI discomfort or headache during the first week. Hypoglycemia symptoms (shakiness, lightheadedness) can occur if combined with other glucose-lowering agents. Limited formal human safety data exists beyond early Phase 1 work.

No. MOTS-c is preclinical with limited human trial data. MOTS-c was on the FDA Category 2 bulk drug substance list until its nominators withdrew it; FDA's Category 2 page (current as of April 22, 2026) lists it as withdrawn. PCAC discussed it on July 23, 2026. No FDA rule has added it to the 503A bulks list, so compounding pharmacies cannot use it today.

MOTS-c is most commonly used by people targeting metabolic health, insulin sensitivity, and exercise performance. Community reports suggest the most noticeable benefits in users over 35 with sedentary backgrounds or metabolic markers trending toward prediabetes. The AMPK activation mechanism overlaps with metformin but through a distinct mitochondrial pathway.